289 related articles for article (PubMed ID: 21492074)
1. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
Rieder S; Michalski CW; Friess H; Kleeff J
Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
[TBL] [Abstract][Full Text] [Related]
2. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
[TBL] [Abstract][Full Text] [Related]
3. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
5. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
7. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
8. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
[TBL] [Abstract][Full Text] [Related]
9. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
Adachi Y; Lee CT; Carbone DP
Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
[TBL] [Abstract][Full Text] [Related]
10. IGF-1R as an anti-cancer target--trials and tribulations.
Chen HX; Sharon E
Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239
[TBL] [Abstract][Full Text] [Related]
11. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
[TBL] [Abstract][Full Text] [Related]
12. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.
Wan X; Harkavy B; Shen N; Grohar P; Helman LJ
Oncogene; 2007 Mar; 26(13):1932-40. PubMed ID: 17001314
[TBL] [Abstract][Full Text] [Related]
14. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
15. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.
Ulanet DB; Ludwig DL; Kahn CR; Hanahan D
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10791-8. PubMed ID: 20457905
[TBL] [Abstract][Full Text] [Related]
16. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2.
Nair PN; De Armond DT; Adamo ML; Strodel WE; Freeman JW
Oncogene; 2001 Dec; 20(57):8203-14. PubMed ID: 11781836
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
Reidy-Lagunes DL; Vakiani E; Segal MF; Hollywood EM; Tang LH; Solit DB; Pietanza MC; Capanu M; Saltz LB
Cancer; 2012 Oct; 118(19):4795-800. PubMed ID: 22437754
[TBL] [Abstract][Full Text] [Related]
19. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
[TBL] [Abstract][Full Text] [Related]
20. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Wojtalla A; Salm F; Christiansen DG; Cremona T; Cwiek P; Shalaby T; Gross N; Grotzer MA; Arcaro A
PLoS One; 2012; 7(10):e47109. PubMed ID: 23056595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]